Skip to content
PubMed This is a summary of 13 peer-reviewed journal articles Updated
Rheumatology · Periodic Fever, Infantile Enterocolitis, and Autoinflammatory Syndrome

Treatment Strategies and Supportive Care for AIFEC

At a Glance

AIFEC has no single standard treatment. Specialists combine medicines that calm the immune system with hydration and nutrition support, then adjust care based on fever, diarrhea, growth, laboratory markers, and how well the child’s gut responds.

Because AIFEC is an ultra-rare disease that was only recently discovered, there is no single “gold standard” or established sequence of treatment that works for every child. Instead, doctors often use a combination of medications to calm the overactive immune system while providing intensive support to help the gut heal. Evidence in NLRC4 disease is largely from small series and case reports, and finding the right balance often involves a period of trial and error [1][2]. Do not start, stop, or change any of these medicines or diets without your specialist team’s guidance.

Targeted Medications

Most treatments for AIFEC aim to block the specific inflammatory proteins (IL-1β and IL-18) that the “stuck-on” NLRC4 sensor is producing. Because of the disease’s rarity, many of these are considered off-label uses.

  • IL-1 Blockers (Anakinra): Anakinra is often one of the first medications tried off-label. It is a daily injection that blocks the IL-1 receptor, preventing the “alarm” signal from spreading [3]. While it can be very effective at stopping fevers, its impact on the bowel inflammation can vary from child to child [4].
  • TNF Inhibitors (Infliximab and Adalimumab): These medications, commonly used for Crohn’s disease, block a protein called TNF. Based on case reports, some children with AIFEC have achieved remission using these off-label drugs, though individual responses vary significantly [5][6].
  • Rapamycin (Sirolimus): This is an off-label immune-suppressing drug that may help stabilize the cells. In some severe case reports, it has been used alongside anakinra to help control life-threatening inflammation [3].
  • Corticosteroids: High-dose steroids (like prednisolone) are often used during an acute flare to quickly lower inflammation. However, they are generally not a long-term solution because of side effects like weakened bones and slowed growth [4].
  • Investigational Therapies: Scientists are studying “IL-18 binding proteins” (Tadekinig alfa) and JAK inhibitors. These are investigational and currently mostly available through clinical trials or special access programs depending on your country [7][8].
  • Hematopoietic Stem Cell Transplantation: In severe, refractory cases, specialists may discuss stem cell transplant as an option, though it carries major risks.

Managing Severe Enterocolitis

While the medications work to stop the underlying “fire,” your child also needs intensive support to manage the damage to their digestive tract (enterocolitis).

Hydration and Electrolytes

Severe diarrhea can lead to rapid dehydration. During a flare, your child may need IV fluids to maintain their blood pressure and replace essential salts (electrolytes) that are lost in the stool [9][10].

Nutritional and Growth Support

Because the inflamed gut often cannot absorb nutrients from regular food, specialized nutrition is a cornerstone of AIFEC care:

  • Elemental Formulas: These are “pre-digested” formulas that are easier for an inflamed gut to handle [11].
  • Feeding Tubes: If a child cannot eat enough to grow, a nasogastric (NG) or gastrostomy (G) tube can deliver nutrition to the stomach, or specialized NJ/GJ tubes can bypass the stomach and feed into the small intestine. Enteral feeding is generally preferred when tolerated.
  • TPN (Total Parenteral Nutrition): In cases of intestinal failure or an inability to tolerate enteral feeds, nutrients are delivered directly into the bloodstream through a central IV line [12]. While TPN can be life-saving, it carries serious risks including central-line infection, thrombosis, and liver complications [13].

The Importance of a Team Approach

Because AIFEC affects so many parts of the body, your child’s care will likely be managed by a team of specialists:

  • Rheumatologists/Immunologists: To manage the medications and the “stuck-on” immune system.
  • Gastroenterologists: To monitor the health of the gut and perform endoscopies if clinically justified.
  • Dietitians: To create a specialized nutrition plan that ensures your child can grow despite the inflammation.

Treatment is a marathon, not a sprint. The goal is to move from managing acute flares to a stable maintenance plan where your child can thrive and the gut has the chance to heal, though no therapy guarantees complete bowel healing [12][6].

Common questions in this guide

What medicines are used to treat AIFEC?
There is no single standard treatment for AIFEC. Specialists may use anakinra, TNF-blocking medicines such as infliximab or adalimumab, rapamycin, or corticosteroids based on the child’s symptoms and response. Some options are off-label or investigational.
How do doctors know whether an AIFEC treatment is working?
The care team may track fever, stool frequency and blood, energy, weight, growth, and blood markers such as ferritin. Improvement in bowel symptoms and the ability to tolerate nutrition are also important. The specialist team decides how long to try a treatment and when to adjust it.
What nutrition support might a child with AIFEC need?
A child may receive elemental formula, which is easier for an inflamed intestine to absorb, through the mouth or a feeding tube. If feeding through the digestive tract is not tolerated or does not provide enough nutrition, total parenteral nutrition can deliver nutrients through a vein. Enteral feeding is generally preferred when it is tolerated.
How does anakinra help children with AIFEC?
Anakinra blocks the receptor for interleukin-1, an inflammatory signal involved in AIFEC. It may reduce fevers, but its effect on intestinal inflammation varies between children. It is commonly used off-label and requires specialist monitoring.
What risks should families know about AIFEC treatments?
Medicines that suppress the immune system can increase the risk of infections, while prolonged high-dose corticosteroids may affect bones and growth. Total parenteral nutrition can cause central-line infections, blood clots, and liver problems. The care team monitors for these complications and balances them against the need to control severe inflammation.
Can a child with AIFEC eventually transition from tube feeding or TPN to regular food?
The possibility depends on how well the intestine heals and whether the child can safely absorb enough nutrition. Specialists may gradually reduce parenteral or tube-based support when oral or enteral feeding is tolerated. Families should make changes only with the child’s nutrition and medical team.

Get notified when new evidence is published on Periodic fever-infantile enterocolitis-autoinflammatory syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (13)
  1. 1

    The 2022 EULAR/ACR points to consider at the early stages of diagnosis and management of suspected haemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS).

    Shakoory B, Geerlinks A, Wilejto M, et al.

    Annals of the rheumatic diseases 2023; (82(10)):1271-1285 doi:10.1136/ard-2023-224123.

    PMID: 37487610
  2. 2

    A Review of Current and Emerging Therapeutic Options for Hemophagocytic Lymphohistiocytosis.

    Summerlin J, Wells DA, Anderson MK, Halford Z

    The Annals of pharmacotherapy 2023; (57(7)):867-879 doi:10.1177/10600280221134719.

    PMID: 36349896
  3. 3

    Rapamycin as an Adjunctive Therapy for NLRC4 Associated Macrophage Activation Syndrome.

    Barsalou J, Blincoe A, Fernandez I, et al.

    Frontiers in immunology 2018; (9()):2162 doi:10.3389/fimmu.2018.02162.

    PMID: 30319625
  4. 4

    Recessive NLRC4-Autoinflammatory Disease Reveals an Ulcerative Colitis Locus.

    Steiner A, Reygaerts T, Pontillo A, et al.

    Journal of clinical immunology 2022; (42(2)):325-335 doi:10.1007/s10875-021-01175-4.

    PMID: 34783940
  5. 5

    Autoinflammation with infantile enterocolitis associated with a novel CARD domain mutation in NLRC4: a case report and literature review.

    Mao Y, Xie Y

    Frontiers in pediatrics 2026; (14()):1878056 doi:10.3389/fped.2026.1878056.

    PMID: 42534928
  6. 6

    Three cases of autoinflammatory disease with novel NLRC4 mutations, and the first mutation reported in the CARD domain of NLRC4 associated with autoinflammatory infantile enterocolitis (AIFEC).

    Asna Ashari K, Parvaneh N, Mirnia K, et al.

    Pediatric rheumatology online journal 2024; (22(1)):90 doi:10.1186/s12969-024-01020-z.

    PMID: 39425177
  7. 7

    NLRC4 inflammasomopathies.

    Romberg N, Vogel TP, Canna SW

    Current opinion in allergy and clinical immunology 2017; (17(6)):398-404 doi:10.1097/ACI.0000000000000396.

    PMID: 28957823
  8. 8

    The Role of Interleukin 18/Interleukin 18-Binding Protein in Adult-Onset Still's Disease and Systemic Juvenile Idiopathic Arthritis.

    Girard-Guyonvarc'h C, Harel M, Gabay C

    Journal of clinical medicine 2022; (11(2)) doi:10.3390/jcm11020430.

    PMID: 35054124
  9. 9

    NLRC4 GOF Mutations, a Challenging Diagnosis from Neonatal Age to Adulthood.

    Bardet J, Laverdure N, Fusaro M, et al.

    Journal of clinical medicine 2021; (10(19)) doi:10.3390/jcm10194369.

    PMID: 34640385
  10. 10

    Rare presentation and retrograde diagnosis of total colonic aganglionosis in a female infant: a case report.

    Chakhunashvili K, Chakhunashvili DG, Kvirkvelia E, Gozalishvili E

    Journal of medical case reports 2023; (17(1)):128 doi:10.1186/s13256-023-03832-1.

    PMID: 37029448
  11. 11

    Exclusive enteral nutrition mediates gut microbial and metabolic changes that are associated with remission in children with Crohn's disease.

    Diederen K, Li JV, Donachie GE, et al.

    Scientific reports 2020; (10(1)):18879 doi:10.1038/s41598-020-75306-z.

    PMID: 33144591
  12. 12

    When parenteral nutrition is the answer: The case of pediatric intestinal rehabilitation.

    Kaenkumchorn TK, Lampone O, Huebner K, et al.

    Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition 2024; (39(5)):991-1002 doi:10.1002/ncp.11179.

    PMID: 38961658
  13. 13

    Autoinflammation with infantile enterocolitis induced by a heterozygous variant (c.1357C > T) in the NLRC4 gene: a case report.

    Wang X, Xiao Y, Ge T, et al.

    Frontiers in pediatrics 2026; (14()):1822554 doi:10.3389/fped.2026.1822554.

    PMID: 42290740

This page provides general information about AIFEC treatment and supportive care and does not constitute medical advice. Your child’s specialist team should guide all medication, nutrition, and transplant decisions; do not start, stop, or change treatment without their advice.